Compare Amgen, Inc. (AMGN) vs Tesla, Inc. (TSLA) Price & Performance

Amgen, Inc.Trade

Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Tesla, Inc. — how do they compare? Amgen, Inc. trades at $412.15 (market cap $224.14B), while Tesla, Inc. trades at $333.26 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 5.8× Amgen, Inc.'s market cap, and Amgen, Inc. pays a 2.43% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.

	AMGN	TSLA
Market Cap	$224.14B	$1.31T
Sector	Health	Consumer Cyclical
52-Week High	$417.20	$489.88
52-Week Low	$271.18	$298.16
Enterprise Value	$267.45B	$1.29T
Dividend Yield	2.43%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

No Aura AI signal available yet.

Tesla, Inc.

Tesla (TSLA) trades at $330.87, up 0.7% on the day, with a bearish technical signal from moving averages and a mixed fundamental picture. The stock shows high valuation multiples (P/E 308.16, P/S 11.36) amid declining profitability, with net income margin falling to 3.67% in 2025 from 15.49% in 2023. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, but Q2 2026 earnings missed expectations.

Outlook remains polarized: analyst consensus price target of $393.87 suggests 19% upside, but high valuation and margin compression pose risks. Key catalysts include autonomy advancements and energy/robotics growth, while competition and execution challenges weigh on sentiment. The stock's trajectory hinges on delivering AI-driven revenue streams beyond automotive.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

TSLA

Investor Ron Baron predicts SpaceX could reach a $40 trillion valuation in 15 years, echoing his successful Tesla bet.24/7 Wall Street · 4 hours agoBullish Tesla shares fall 26% YTD, seen overvalued at $333 amid weak margins and costly growth bets.24/7 Wall Street · 5 hours agoBearish Tesla CEO Musk's 2025 pay plan could skip milestones if Tesla is acquired, potentially unlocking $824B payout.24/7 Wall Street · 5 hours agoNeutral View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.